Product Information
CYCLOSPORINE MODIFIED 100 MG/ML is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $2.0368 per ML under NDC 00172731320. Its NADAC has been published 355 times since Nov 28, 2013.
FDA first approved this application on Mar 25, 2005. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100 mg/mL
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00172731320
Classification
Generic
Dosage Form
SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CYCLOSPORINEApproval Type
Generic (ANDA)
FDA Application
ANDA065078FDA Approved
3/25/2005
TE Code
AB1
On Market Since
3/29/2005
Pharmacological Classes
Price Statistics
The NADAC for CYCLOSPORINE MODIFIED 100 MG/ML has been published 355 times since Nov 28, 2013, and over the history we have for it it has declined 31.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.0368 per ML |
|---|---|
| All-time high | $4.6427 (Feb 11, 2015) |
| All-time low | $1.7080 (Aug 21, 2024) |
| 52-week high | $2.7888 |
| 52-week low | $2.0368 |
| Median price | $2.7888 |
| Average price | $2.7674 |
| Largest weekly change | +54.8% (Nov 19, 2014) |
| Weeks tracked | 355 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cyclosporine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CYCLOSPORINE MODIFIED 100 MG/ML?
The current National Average Drug Acquisition Cost (NADAC) for CYCLOSPORINE MODIFIED 100 MG/ML, manufactured by Teva Pharmaceuticals USA Inc., is $2.0368 per ML (NDC 00172731320), effective Sep 30, 2026.
How has the price of CYCLOSPORINE MODIFIED 100 MG/ML changed over time?
Over the history we have for it, the NADAC for CYCLOSPORINE MODIFIED 100 MG/ML has declined 31.6%. It has been tracked across 355 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CYCLOSPORINE MODIFIED 100 MG/ML?
Since Nov 28, 2013, the NADAC for CYCLOSPORINE MODIFIED 100 MG/ML has ranged from a low of $1.7080 (Aug 21, 2024) to a high of $4.6427 (Feb 11, 2015), with a median of $2.7888 per ML.
Are there cheaper alternatives to CYCLOSPORINE MODIFIED 100 MG/ML?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as CYCLOSPORINE MODIFIED 100 MG/ML in a comparable dosage form, but none are currently priced below it.
Who manufactures CYCLOSPORINE MODIFIED 100 MG/ML?
CYCLOSPORINE MODIFIED 100 MG/ML (NDC 00172731320) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.